表紙
市場調查報告書
商品編碼
1020961

抗發炎藥的成長機會、成長預測 (2021-2028年):各藥物類別、各適應症、地區

Anti-Inflammatory Therapeutics Market by Drug Class, Indication Type : Global Opportunity Analysis and Industry Forecast, 2021-2028

出版日期: | 出版商: Allied Market Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球抗發炎藥的市場規模在預測期間內預計以4.0%的年複合成長率發展,從2020年的980億2600萬美元,成長到2028年1255億5200萬美元的規模。

自體免疫疾病和呼吸疾病發病率增加,開發平台中新藥的存在,抗發炎藥的採用劇增等要素促進該市場成長。還有比傳統藥物有針對性,效果高,副作用少的抗發炎生技藥品登場,抗發炎藥的需求大幅度增加。再加上抗發炎治療藥的認知度高漲,對市場成長也有大幅貢獻。同時,創新的醫藥品的專利到期,及副作用的發生率高妨礙市場進一步成長。

本報告提供全球抗發炎藥的市場調查,市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,市場規模的變化、預測,醫藥品分類、適應症、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義、範圍
  • 主要調查結果
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 市場動態

第4章 市場分析、預測:各醫藥品分類

  • 抗發炎生技藥品
  • 非類固醇消炎劑(NSAID)
  • 皮質類固醇
    • 主要趨勢、成長機會
    • 市場規模、預測
    • 市場分析:各國

第5章 市場分析、預測:各適應症

  • 關節炎
  • 乾癬
  • 呼吸疾病
  • 多發性硬化症
  • 抗發炎性腸道疾病(IBD)
  • 其他
    • 市場規模、預測
    • 市場分析:各國

第6章 市場分析、預測:各地區、主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 南美、中東、非洲
    • 主要趨勢、成長機會
    • 市場規模、預測:各國
    • 市場規模、預測:各醫藥品分類
    • 市場規模、預測:各適應症

第7章 企業簡介

  • Amgen Inc
  • AstraZeneca PLC.
  • Eli Lily and Company.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • PFIZER INC.
目錄
Product Code: A00196

The global anti-inflammatory therapeutics market size was $98,026 million in 2020 and is projected to reach $125,552 million by 2028, registering a CAGR of 4.0% from 2021 to 2028.

Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants, and microorganisms. Inflammation is the mechanism of innate immunity, which seeks to eliminate the cause of injury, clear the dead & necrotic cells, and heal the injured tissues. Sometimes, the body's defense system inappropriately triggers inflammation against its own cells, resulting in Anti-inflammatory autoimmune diseases. Reducing inflammation is one of the primary therapeutic strategies in acute as well as chronic diseases.

Anti-inflammatory therapeutics help in easing acute and chronic pain. For instance, they are used to treat migraines & headaches, rheumatic arthritis, sprains, or even menstrual pain. These therapeutics can provide faster relief as compared with other drugs. In addition, they are capable of lowering the levels of prostaglandins and the chemicals responsible for inflammation as well as reducing pain and swelling.

Anti-inflammatory drugs usually target the anti-inflammatory mediators or enzymes. These drugs are often used in combination of other drugs. Inflammation is the most prevalent treatable symptom in many immune and respiratory disease. Hence, the global market has witnessed an increased adoption of biologics.

Increase in incidence of autoimmune & respiratory conditions, new drugs in pipeline, and surge in adoption of anti-inflammatory drugs acts as the key driving forces of the global anti-inflammatory market. In addition, the demand for anti-inflammatory drugs has been increasing considerably, owing to the emergence of anti-inflammatory biologics that are more targeted, effective, and with lesser side effects as compared to conventional drugs. Moreover, increase in awareness of anti-inflammatory therapeutics significantly contributes toward the growth of the market. However, pending patent expirations of innovative drugs and higher incidence of side effects of anti-inflammatory drugs hamper the market growth.

The global anti-inflammatory therapeutics market is segmented into indication, drug class, and region. On the basis of indication, the market is differentiated into arthritis, respiratory diseases, multiple sclerosis, psoriasis, anti-inflammatory bowel disease (IBD), and other anti-inflammatory diseases. Depending on drug class, it is segregated into nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologics. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the key players operating in the anti-inflammatory therapeutic market are Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis, F. Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC, and Amgen, Ferring Pharmaceuticals, Bioventus, Zimmer Biomet Holdings, Inc., and Flexion Therapeutics, Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative analysis along with the current global Anti-inflammatory therapeutics market trends from 2020 to 2028 to identify the prevailing opportunities along with the strategic assessment.
  • The anti-inflammatory therapeutics market forecast is studied from 2020 to 2028.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Drug Class

  • Nonsteroidal Anti-inflammatory Diseases (NSAIDs)
  • Corticosteroids
  • Biologics

By Indication Type

  • Arthritis
  • Respiratory Disease
  • Multiple Sclerosis
  • Psoriasis
  • Anti-Inflammatory Bowel Disease (IBD)
  • Other Anti-inflammatory disease

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe

KEY MARKET PLAYERS

  • Pfizer, Inc.
  • Abbvie, Inc.
  • Johnson & Johnson
  • GlaxoSmithKline
  • Merck & CO., Inc.
  • Novartis AG
  • F. Hoffman, La Roche AG
  • Eli Lily and Company
  • AstraZeneca PLC
  • Amgen.

List of other players in the value chain (profiles not included in the report):

  • Ferring Pharmaceuticals
  • Bioventus
  • Zimmer Biomet Holdings, Inc.
  • Flexion Therapeutics, Inc.
  • Analogic Corporation

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key Findings
    • 3.2.1.Top Investment Pockets
    • 3.2.2.Key forces shaping the anti-inflammatory therapeutics market
  • 3.3.Market dynamics
    • 3.3.1.Drivers
      • 3.3.1.1.Rising incidences of autoimmune and respiratory conditions
      • 3.3.1.2.New drug pipelines
      • 3.3.1.3.Increasing adoption rate of anti -Inflammatory drugs
    • 3.3.2.Restraint
      • 3.3.2.1.side effects of anti -Inflammatory drugs
      • 3.3.2.2.Patent expires
    • 3.3.3.Opportunity
      • 3.3.3.1.Developing biosimilars for the existing drugs
  • 3.4.Market dynamics

CHAPTER 4:GLOBAL ANTI -INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Anti- Inflammatory Biologics
    • 4.2.1.Key market trends and opportunities
    • 4.2.2.Market size and forecast
    • 4.2.3.Market analysis, by country
  • 4.3.Nonsteroidal Anti- -Inflammatory Drugs (NSAIDs)
    • 4.3.1.Key trends and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Corticosteroids
    • 4.4.1.Key market trends and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country

CHAPTER 5:GLOBAL ANTI-INFLAMMATORY HERAPEUTICS MARKET BY INDICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Arthritis.
    • 5.2.1.Market size and forecast
    • 5.2.2.Market analysis, by country
  • 5.3.Psoriasis
    • 5.3.1.Market size and forecast
    • 5.3.2.Market analysis, by country
  • 5.4.Respiratory Diseases
    • 5.4.1.Market size and forecast
    • 5.4.2.Market analysis, by country
  • 5.5.Multiple sclerosis
    • 5.5.1.Market size and forecast
    • 5.5.2.Market analysis, by country
  • 5.6.Anti-Inflammatory Bowel Disease (IBD)
    • 5.6.1.Market size and forecast
    • 5.6.2.Market analysis, by country
  • 5.7.Other Anti-Inflammatory disease
    • 5.7.1.Market size and forecast
    • 5.7.2.Market analysis, by country

CHAPTER 6:ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY REGION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.North America
    • 6.2.1.Key trends and opportunities
    • 6.2.2.Market size and forecast, by country
    • 6.2.3.Market size and forecast, by drug class
    • 6.2.4.Market size and forecast, by Indication
    • 6.2.5.U.S.
      • 6.2.5.1.U.S. market size and forecast, by drug class
      • 6.2.5.2.U.S. market size and forecast, by Indication
    • 6.2.6.Canada
      • 6.2.6.1.Canada market size and forecast, by drug class
      • 6.2.6.2.Canada market size and forecast, by Indication
    • 6.2.7.Mexico
      • 6.2.7.1.Mexico market size and forecast, by drug class
      • 6.2.7.2.Mexico market size and forecast, by Indication
  • 6.3.Europe
    • 6.3.1.Key trends and opportunities
    • 6.3.2.Europe market size and forecast, by country
    • 6.3.3.Europe market size and forecast, by drug class
    • 6.3.4.Europe market size and forecast, by Indication
    • 6.3.5.Germany
      • 6.3.5.1.Germany market size and forecast, by drug class
      • 6.3.5.2.Germany market size and forecast, by Indication
    • 6.3.6.UK
      • 6.3.6.1.UK market size and forecast, by drug class
      • 6.3.6.2.UK market size and forecast, by Indication
    • 6.3.7.Spain
      • 6.3.7.1.Spain market size and forecast, by drug class
      • 6.3.7.2.Spain market size and forecast, by Indication
    • 6.3.8.France
      • 6.3.8.1.France market size and forecast, by drug class
      • 6.3.8.2.France market size and forecast, by Indication
    • 6.3.9.Italy
      • 6.3.9.1.Italy market size and forecast, by drug class
      • 6.3.9.2.Italy market size and forecast, by Indication
    • 6.3.10.Rest of Europe
      • 6.3.10.1.Rest of Europe market size and forecast, by drug class
      • 6.3.10.2.Rest of Europe market size and forecast, by Indication
  • 6.4.Asia-Pacific
    • 6.4.1.Key trends and opportunities
    • 6.4.2.Asia-Pacific market size and forecast, by country
    • 6.4.3.Asia-Pacific market size and forecast, by drug class
    • 6.4.4.Asia-Pacific market size and forecast, by Indication
    • 6.4.5.Japan
      • 6.4.5.1.Japan market size and forecast, by drug class
      • 6.4.5.2.Japan market size and forecast, by Indication
    • 6.4.6.China
      • 6.4.6.1.China market size and forecast, by drug class
      • 6.4.6.2.China market size and forecast, by Indication
    • 6.4.7.India
      • 6.4.7.1.India market size and forecast, by drug class
      • 6.4.7.2.India market size and forecast, by Indication
    • 6.4.8.Australia
      • 6.4.8.1.Australia market size and forecast, by drug class
      • 6.4.8.2.Australia market size and forecast, by Indication
    • 6.4.9.South Korea
      • 6.4.9.1.South Korea market size and forecast, by drug class
      • 6.4.9.2.South Korea market size and forecast, by Indication
    • 6.4.10.Rest of Asia-Pacific
      • 6.4.10.1.Rest of Asia-Pacific market size and forecast, by drug class
      • 6.4.10.2.Rest of Asia-Pacific market size and forecast, by Indication
  • 6.5.LAMEA
    • 6.5.1.Key market trends and opportunities
    • 6.5.2.LAMEA market size and forecast, by country
    • 6.5.3.LAMEA market size and forecast, by drug class
    • 6.5.4.LAMEA market size and forecast, by Indication
    • 6.5.5.Brazil
      • 6.5.5.1.Brazil market size and forecast, by drug class
      • 6.5.5.2.Brazil market size and forecast, by Indication
    • 6.5.6.South Africa
      • 6.5.6.1.South Africa market size and forecast, by drug class
      • 6.5.6.2.South Africa market size and forecast, by Indication
    • 6.5.7.Saudi Arabia
      • 6.5.7.1.Saudi Arabia market size and forecast, by drug class
      • 6.5.7.2.Saudi Arabia market size and forecast, by Indication
    • 6.5.8.Rest of LAMEA
      • 6.5.8.1.Rest of LAMEA market size and forecast, by drug class
      • 6.5.8.2.Rest of LAMEA market size and forecast, by Indication

CHAPTER 7:COMPANY PROFILES

    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product portfolio
    • 7.1.5.Business performance
    • 7.1.6.Key strategic moves and developments
  • 7.2.Amgen Inc
    • 7.2.1.Company overview
    • 7.2.2.Company snapshot
    • 7.2.3.Operating business segments
    • 7.2.4.Product Portfolio
    • 7.2.5.Business performance
    • 7.2.6.Key strategic moves and developments
  • 7.3.AstraZeneca PLC.
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Operating business segments
    • 7.3.4.Product Portfolio
    • 7.3.5.Business performance
  • 7.4.Eli Lily and Company.
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Operating business segments
    • 7.4.4.Product portfolio
    • 7.4.5.Business performance
  • 7.5.F. Hoffmann-La Roche AG
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Operating business segments
    • 7.5.4.Product portfolio
    • 7.5.5.Business performance
    • 7.5.6.Key strategic moves and developments
  • 7.6.GlaxoSmithKline plc
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
    • 7.6.5.Business performance
  • 7.7.Johnson & Johnson
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Operating business segments
    • 7.7.4.Product portfolio
    • 7.7.5.Business performance
  • 7.8.Merck & Co., Inc.
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product portfolio
    • 7.8.5.Business performance
  • 7.9.Novartis AG
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product portfolio
    • 7.9.5.Business performance
  • 7.10.PFIZER INC.
    • 7.10.1.Company overview
    • 7.10.2.Company snapshot
    • 7.10.3.Operating business segments
    • 7.10.4.Product portfolio
    • 7.10.5.Business performance
    • 7.10.6.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 02.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ANTI-INFLAMMATORY BIOLOGICS, BY REGION, 2020-2028 ($MILLION)
  • TABLE 03.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR NONSTEROIDAL ANTI -INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2020-2028 ($MILLION)
  • TABLE 04.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR CORTICOSTEROIDS, BY REGION, 2020-2028 ($MILLION)
  • TABLE 05.ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 06.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ARTHRITIS, BY REGION, 2020-2028 ($MILLION)
  • TABLE 07.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR PSORIASIS, BY REGION, 2020-2028 ($MILLION)
  • TABLE 08.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR RESPIRATORRY DISEASE, BY REGION, 2020-2028 ($MILLION)
  • TABLE 09.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2020-2028 ($MILLION)
  • TABLE 10.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR IANTI-INFLAMMATORY BOWEL DISEASE (IBD), BY REGION, 2020-2028 ($MILLION)
  • TABLE 11.ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR OTHER IANTI-INFLAMMATORY DISEASE, BY REGION, 2020-2028 ($MILLION)
  • TABLE 12.ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY REGION, 2020-2028 ($MILLION)
  • TABLE 13.NORTH AMERICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 14.NORTH AMERICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028($MILLION)
  • TABLE 15.NORTH AMERICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 16.U.S. ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 17.U.S. ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 18.CANADA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 19.CANADA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 20.MEXICO ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028($MILLION)
  • TABLE 21.MEXICO ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 22.EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 23.EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 24.EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 25.GERMANY ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 26.GERMANY ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 27.UK ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 28.UK ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 29.SPAIN ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 30.SPAIN ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 31.FRANCE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 32.FRANCE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 33.ITALY ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 34.ITALY ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 35.REST OF EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 36.REST OF EUROPE ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028($MILLION)
  • TABLE 37.ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY COUNTRY, 2020-2026 ($MILLION)
  • TABLE 38.ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 39.ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 40.JAPAN ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 41.JAPAN ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 42.CHINA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 43.CHINA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 44.INDIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 45.INDIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 46.AUSTRALIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
  • TABLE 47.AUSTRALIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 48.SOUTH KOREA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 49.SOUTH KOREA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 50.REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 51.REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 52.LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY COUNTRY, 2020-2028 ($MILLION)
  • TABLE 53.LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 54.LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 55.BRAZIL ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 56.BRAZIL ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 57.SOUTH AFRICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 58.SOUTH AFRICA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 59.SAUDI ARABIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 60.SAUDI ARABIA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 61.REST OF LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY DRUG CLASS, 2020-2028 ($MILLION)
  • TABLE 62.REST OF LAMEA ANTI-INFLAMMATORY THEAUPEUTIC MARKET, BY INDICATION, 2020-2028 ($MILLION)
  • TABLE 63.ABBVIE: COMPANY SNAPSHOT
  • TABLE 64.ABBVIE: OPERATING SEGMENTS
  • TABLE 65.ABBVIE: PRODUCT PORTFOLIO
  • TABLE 66.AMGEN: COMPANY SNAPSHOT
  • TABLE 67.AMGEN: OPERATING SEGMENTS
  • TABLE 68.AMGEN: PRODUCT PORTFOLIO
  • TABLE 69.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 70.ASTRAZENECA: BUSINESS SEGMENT
  • TABLE 71.ELI LILLY: COMPANY SNAPSHOT
  • TABLE 72.ELI LILLY: OPERATING SEGMENTS
  • TABLE 73.ELI LILLY: PRODUCT PORTFOLIO
  • TABLE 74.ROCHE: COMPANY SNAPSHOT
  • TABLE 75.ROCHE: OPERATING SEGMENTS
  • TABLE 76.ROCHE: PRODUCT PORTFOLIO
  • TABLE 77.GLAXOSMITHKLINE: COMPANY SNAPSHOT
  • TABLE 78.GLAXOSMITHKLINE: OPERATING SEGMENTS
  • TABLE 79.GLAXOSMITHKLINE: PRODUCT PORTFOLIO
  • TABLE 80.JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 81.JOHNSON & JOHNSON: OPERATING SEGMENTS
  • TABLE 82.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 83.MERCK: COMPANY SNAPSHOT
  • TABLE 84.MERCK: OPERATING SEGMENTS
  • TABLE 85.MERCK: PRODUCT PORTFOLIO
  • TABLE 86.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 87.NOVARTIS: OPERATING SEGMENTS
  • TABLE 88.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 89.PFIZER: COMPANY SNAPSHOT
  • TABLE 90.PFIZER: OPERATING SEGMENTS
  • TABLE 91.PFIZER: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.ANTI-INFLAMMATORY THERAPEUTIC MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05.MODERATE THREAT OF SUBSTITUTION
  • FIGURE 06.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07.MODERATE COMPETITVE RIVARLY
  • FIGURE 08.ANTI-INFLAMMATORY THERAPEUTIC MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 09.COMPARATIVE SHARE ANALYSIS OF ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ANTI- -INFLAMMATORY BIOLOGICS, BY COUNTRY, 2020 & 2028(%)
  • FIGURE 10.COMPARATIVE SHARE ANALYSIS OF ENTERAL ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR NONSTEROIDAL ANTI -INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2020 & 2028 (%)64
  • FIGURE 11.COMPARATIVE SHARE ANALYSIS OF ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 12.COMPARATIVE SHARE ANALYSIS OF CANCER ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ARTHRITIS, BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CANCER ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ARTHRITIS, BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR RESPIRATORY DISEASE, BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR MULTIPLE SCLEROSIS BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR ANTI-INFLAMMATORY BOWEL DISEASE (IBD) BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ANTI-INFLAMMATORY THEAUPEUTIC MARKET FOR OTHER ANTI-INFLAMMATORY DISEASE BY COUNTRY, 2020 & 2028 (%)
  • FIGURE 18.ABBVIE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 19.ABBVIE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 20.ABBVIE: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 21.NET SALES, 2018-2020 ($MILLION)
  • FIGURE 22.AMGEN: NET SALES BY DIVISION, 2020 (%)
  • FIGURE 23.AMGEN: NET SALES BY REGION, 2020 (%)
  • FIGURE 24.NET SALES, 2018-2020 ($MILLION)
  • FIGURE 25.ASTRAZENECA REVENUE SHARE BY BUSINESS UNIT, 2020 (%)
  • FIGURE 26.ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 27.NET SALES, 2018-2020 ($MILLION)
  • FIGURE 28.ELI LILLY REVENUE SHARE BY BUSINESS UNIT, 2020 (%)
  • FIGURE 29.ELI LILLY: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 30.ROCHE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 31.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 32.ROCHE: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 33.GLAXOSMITHKLINE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 34.GLAXOSMITHKLINE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 35.GLAXOSMITHKLINE: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 36.NET SALES, 2018-2020 ($MILLION)
  • FIGURE 37.JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 38.JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 39.NET SALES, 2018-2020 ($MILLION)
  • FIGURE 40.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 41.MERCK: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 42.NOVARTIS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 43.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 44.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 45.PFIZER NET SALES, 2019-2020 ($MILLION)
  • FIGURE 46.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 47.PFIZER: REVENUE SHARE BY GEOGRAPHY, 2018 (%)